Chicago - Fluocinolone acetonide (0.01 percent) in a blend of mineral oils and refined peanut oil is an effective therapy for pediatric atopic dermatitis, even in children with peanut allergy, according to Amy S. Paller, M.D.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.